

## 3Q16

### MARKET CAPITALIZATION

R\$30.5 billion (Sep 30, 2016)

### 3Q16 SHARE COUNT

Weighted avg: 1,787,403,276

End of period: 1,787,429,549

### STOCK PERFORMANCE

Quarter to end of Sep'16: -6.1%

### CONFERENCE CALL (English)

Date: November 14<sup>th</sup>, 2016.

Time: 1p.m. (BrT) / 10a.m. (NYT)

Brazil: +55 (11) 3193-1001

+55 (11) 2820-4001

USA: +1 (866) 262-4553

International: +1 (412) 317-6029

Password: BMFBOVESPA

### Live webcast and presentation:

[www.ccall.com.br/bmfbovespa/3q16.htm](http://www.ccall.com.br/bmfbovespa/3q16.htm)



[www.bmfbovespa.com.br/ir](http://www.bmfbovespa.com.br/ir)

## BM&FBOVESPA ANNOUNCES RESULTS FOR THE THIRD QUARTER OF 2016

*Weak performance in the BM&F segment led revenues to decline 6.3% in the quarter compared to 3Q15. Nonetheless, the Bovespa segment and revenues from other business grew in the quarter by 9.0% and 3.5% respectively;*

*3Q16 expenses were negatively impacted by extraordinary provisions for legal contingencies; adjusted expenses<sup>1</sup> fell 5.0% year-over-year;*

**São Paulo, Brazil, November 11, 2016** – BM&FBOVESPA S.A. (ticker: BVMF3) today reported its third-quarter earnings for the period ending on September 30, 2016 (3Q16). In this quarter, lower volumes and revenues per contract (RPC) in BM&F segment drove revenue to a 6.3% decrease compared to the same period of the previous year (3Q15). 3Q16 expenses were impacted by extraordinary items, mainly related to provisions and the proposed business combination with Cetip<sup>2</sup>.

BM&FBOVESPA reaffirms its previously announced 2016 budget ranges: (i) adjusted expenses (OPEX) from R\$640 million to R\$670 million; and (ii) capital expenditures (CAPEX) from R\$200 million to R\$230 million.

### Highlights of the 3Q16:

In the BM&F segment, average daily volume (ADV) and RPC decreased 11.7% and 12.9%, respectively over 3Q15;

Average daily trading value (ADTV) in the Bovespa segment reached R\$6.9 billion in 3Q16, an increase of 5.9% over the same period of the previous year, as a consequence of a higher average market capitalization;

Other revenues not tied to volumes grew 3.5% compared to 3Q15, mainly driven by an increase of 31.1% in the depository line;

Adjusted expenses reached R\$155.5 million in 3Q16, a decrease of 5.0% over 3Q15;

Financial result reached R\$221.5 million, 157.5% higher over 3Q15, reflecting higher average cash balance to fund the proposed combination with Cetip;

R\$146.7 million in interest on capital, totaling 50% of 3Q16 IFRS net income;

Chief Executive Officer of BM&FBOVESPA, Edemir Pinto, said: “We are moving forward to implement the second phase of the new integrated BM&FBOVESPA Clearinghouse in the first quarter of 2017, which is the last major infrastructure project we are deploying for our clients and market participants and will extend to the equity market the capital efficiency brought by CORE and already available in the financial and commodities derivatives market. By concluding this strategic project, we will be able to shift our focus more heavily towards product and market development initiatives, in order to continue to address the demands received from our clients. While we wait for regulators to approve our business combination with CETIP, we have begun work, within the boundaries set by regulation, in planning some aspects of the integration. Our focus will be to bring together the teams in a way that preserves the cultures of both organizations, maintains the operating and technological excellence in delivering services for the market and regulators, enhances services offered to clients, and captures potential synergies”.

Chief Financial and Investor Relations Officer, Daniel Sonder, commented: “Weak performance in the derivatives market coupled with some non-cash extraordinary expenses hurt our operational performance from an accounting perspective, which did not affect our financial robustness. At this point, we are waiting for the conclusion of the regulatory approval process of the transaction with Cetip and in order to meet the financial needs related to the settlement of the cash portion of this transaction we are retaining a large cash balance, which had a positive impact on our financial result this quarter and structuring a debt issuance. While the transaction with Cetip is not concluded we continue to deliver on key financial metrics, with diligent expense control, executing our projects and developing products and markets”.

### Income statement summary (in R\$ millions)

	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)	9M16	9M15	9M16/9M15 (%)
Net revenues	559.1	598.3	-6.5%	574.5	-2.7%	1,697.1	1,673.4	1.4%
Expenses	(446.1)	(217.8)	104.8%	(268.8)	66.6%	(917.0)	(637.3)	43.9%
Operating income	113.0	380.5	-70.3%	305.7	-63.0%	780.2	1,036.1	-24.7%
Operating margin	20.2%	63.6%	-4,338 bps	53.2%	-3,300 bps	46.0%	61.9%	-1,595 bps
Financial result	221.5	86.0	157.5%	(418.3)	-153.0%	(36.2)	219.0	-116.5%
IFRS net income (loss)*	293.5	2,012.5	-85.4%	(114.4)	-356.5%	518.4	2,610.0	-80.1%
Adjusted expenses	(155.5)	(163.6)	-5.0%	(146.7)	6.0%	(446.5)	(443.9)	0.6%

\*Attributable to BM&FBOVESPA shareholders.

<sup>1</sup> Adjusted to (i) depreciation and amortization; (ii) stock grant plan costs – principal and payroll taxes – and stock option plan; (iii) transaction cost and planning of the proposed business combination with Cetip that is still pending regulatory approval; and (iv) transfer of fines, provisions and incentive programs to market participants.

<sup>2</sup> Pending regulatory approvals from the Brazilian Securities and Exchange Commission (CVM), Central Bank of Brazil (BACEN) and Antitrust Authority (CADE).

## ANALYSIS OF 3Q16 FINANCIAL RESULTS

### REVENUES

**Total revenues:** BM&FBOVESPA posted total revenue of R\$621.3 million, 6.3% lower than in 3Q15. This performance was a result of a decrease in BM&F segment revenue, which was partially offset by an increase of Bovespa segment revenue and revenues not tied to volumes traded.


Revenues from trading and post-trading in the derivatives and equities markets together represented 76.2% of total revenues in 3Q16, reaching R\$473.3 million, a 9.1% decrease year-over-year.

**BM&F segment – trading, clearing and settlement:** reached R\$240.6 million (38.7% of total revenue), down 21.6% compared to 3Q15, explained by an 11.7% reduction in the ADV coupled with an average RPC that was 12.9% lower (see performance by segment section).

**Bovespa segment – trading, clearing and settlement:** totaled R\$241.8 million (38.9% of total revenues), a 9.0% increase over 3Q15. Trading and post-trading (transactions) revenues reached R\$237.3 million in 3Q16, 8.0% higher compared to the same period of the previous year, mainly due to an increase of 5.9% in the ADTV (see performance by segment section).

The derivatives markets were the main sources of revenue for the Company (41.8% of total revenues), with financial and commodity derivatives in the BM&F segment accounting for 38.0% and options/forwards on single stocks and indices in the Bovespa segment generating the other 3.8%. In addition, USD-linked revenues accounted for 22.3% of the Company's total revenue.

3Q16 Revenues Breakdown<sup>3</sup> (% of total revenues)



**Other revenues:** revenues not tied to volumes reached R\$138.9 million in 3Q16 (22.4% of total revenues), a 3.5% increase year-over-year. The highlights were:

- ✓ **Securities lending:** reached R\$30.2 million (4.9% of total revenues), 6.8% higher than 3Q15, explained mainly by a 4.8% increase in the average financial value of open interest positions in the securities lending platform.
- ✓ **Depository, custody and back office:** totaled R\$47.4 million (7.6% of total revenues), a 31.1% increase over 3Q15, as a result of 57.7% growth in revenues from *Tesouro Direto*, which reached R\$18.7 million in 3Q16, and adjustments of certain depository services' prices by inflation in Jan'16.
- ✓ **Market data (vendors):** revenues from market data sales amounted to R\$24.6 million (4.0% of total revenues), down 19.2% over 3Q15, explained by: (i) a decrease in the number of users and migration of clients to lower cost market data packages; and (ii) the appreciation of the Brazilian Real against the US Dollar, since 66.0% of this revenue line was denominated in US Dollars in 3Q16.

**Net Revenues:** net revenues decreased 6.5% year-over-year, reaching R\$559.1 million in 3Q16.

### EXPENSES

**Expenses:** totaled R\$446.1 million in 3Q16. The 104.8% growth compared to 3Q15 is mainly explained by extraordinary expenses, with no cash impact, related to provisions for legal contingencies.

**Adjusted expenses:** reached R\$155.5 million in 3Q16, a 5.0% decrease year-over-year. In the nine months to Sep'16 adjusted expenses reached R\$446.5 million, flat compared to the same period of the previous year.

<sup>3</sup> The revenues breakdown showed in the chart includes the revenues lines "others" for the Bovespa segment and "foreign exchange" and "securities" for the BM&F segment, as reported in the audited financial statements note 20, within other revenues not tied to volumes traded.

## Reconciliation of adjusted expenses (in R\$ millions)

	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)	9M16	9M15	9M16/9M15 (%)
<b>Total expenses</b>	<b>446.1</b>	<b>217.8</b>	<b>104.8%</b>	<b>268.8</b>	<b>66.0%</b>	<b>917.0</b>	<b>637.3</b>	<b>43.9%</b>
Depreciation	(25.1)	(26.1)	-3.8%	(23.8)	5.8%	(72.7)	(84.8)	-14.3%
Stock grant/option	(21.1)	(19.4)	8.6%	(41.2)	-48.8%	(87.7)	(84.9)	3.3%
Proposed business combination with Cetip	(0.7)	-	-	(46.3)	-98.5%	(48.0)	-	-
Planning of the business integration with Cetip	(6.5)	-	-	(1.5)	324.4%	(8.0)	-	-
Provisions and others	(237.3)	(8.7)	2634.8%	(9.4)	2431.8%	(254.1)	(23.6)	975.6%
<b>Adjusted expenses</b>	<b>155.5</b>	<b>163.6</b>	<b>-5.0%</b>	<b>146.7</b>	<b>6.0%</b>	<b>446.5</b>	<b>443.9</b>	<b>0.6%</b>

**Personnel:** totaled R\$105.2 million in 3Q16, a drop of 1.1% year-over-year. The annual wage adjustment of 8.6%, applied from Aug'16 over the entire payroll and the increase of 8.6% in stock grant expenses<sup>4</sup>, were offset by other items, notably, the R\$6.7 million increase in capitalized personnel expenses related to ongoing technology projects, mainly, the development of the equities phase of the BM&FBOVESPA Clearinghouse.

🌱 **Adjusted personnel:** decreased 3.3% year-over-year to R\$84.1 million. The annual salary adjustment applied in Aug'16 was offset by an increase in capitalized personnel expenses, as mentioned above.

## Reconciliation of adjusted personnel (in R\$ millions)

	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)	9M16	9M15	9M16/9M15 (%)
<b>Personnel expenses</b>	<b>105.2</b>	<b>106.4</b>	<b>-1.1%</b>	<b>126.0</b>	<b>-16.5%</b>	<b>337.4</b>	<b>336.5</b>	<b>0.3%</b>
Stock grant/option	(21.1)	(19.4)	8.6%	(41.2)	-48.8%	(87.7)	(84.9)	3.3%
<b>Adjusted personnel expenses</b>	<b>84.1</b>	<b>87.0</b>	<b>-3.3%</b>	<b>84.8</b>	<b>-0.8%</b>	<b>249.8</b>	<b>251.6</b>	<b>-0.7%</b>

**Data processing:** totaled R\$36.9 million, 21.3% higher compared to 3Q15, mainly explained by: (i) IT maintenance contracts adjustments; and (ii) the impact of the appreciation of the US Dollar against the Brazilian Real between Jan'15 and Dec'15, given that a cash flow hedge<sup>5</sup> was set up for a portion of the contracts denominated in foreign currency in those months.

**Transaction with Cetip:** amounted to R\$7.2 million in 3Q16, composed of extraordinary expenses connected to the proposed business combination with Cetip, R\$0.7 million in transaction costs<sup>6</sup> and R\$6.5 million in expenses related to planning of the business integration<sup>7</sup>, which will happen after regulatory approval.

**Others:** totaled R\$246.2 million and includes: (i) extraordinary expenses of R\$183.9 million in provisions related to a lawsuit whose prospect of defeat was assessed as probable, (previously classified as possible), after the decision was upheld, on appeal, against the Company<sup>8</sup>; and (ii) R\$47.4 million in provisions for success fees to legal advisors that, from 3Q16 onwards, are made for lawsuits whose prospect of defeat are assessed as possible or remote. With regard to the amount, this is an extraordinary impact and aims to better report on the Company's balance sheet cash disbursements that may occur in the future.

**Operating income:** totaled R\$113.0 million. Excluding extraordinary items connected to: (i) extraordinary provisions related to lawsuits and (ii) the proposed business combination with Cetip, this line would have totaled R\$351.5 million.

## OTHER FINANCIAL HIGHLIGHTS

**Cash and cash equivalents:** short- and long-term cash, cash equivalents and financial investments as of September 30, 2016 amounted to R\$10,717.3 million<sup>9</sup>, including R\$1,681.8 million in third party cash (mainly related to cash collateral pledged to the Company's clearinghouses). BM&FBOVESPA's own cash totaled R\$8,499.5 million and is comprised of: (i) between R\$2.0 billion and R\$2.5 billion cash which makes up the Company's usual liquidity requirements to run the business (including R\$982.2 million in restricted financial resources formally tied to the clearinghouses' safeguard structure); and (ii) unrestricted available cash which will be used to fund the proposed transaction with Cetip (including proceeds from the sale of CME Group shares, amounting to R\$5,487.7 million<sup>10</sup>, before tax).

**Indebtedness:** at the end of 3Q16, the Company had R\$2,020.1 million in gross debt outstanding (including principal and accrued interest), composed of US\$612.0 million senior unsecured notes issued in Jul'10 (2020 Notes). Since the end of Mar'16, the principal amount of the 2020 Notes has been

<sup>4</sup> Stock grant expenses totaled R\$21.0 million and were composed of: (i) R\$11.7 million in principal and (ii) R\$9.3 million in payroll tax provision to be paid upon the delivery of shares to the beneficiaries.

<sup>5</sup> The Company allocated part of its cash position in foreign currency to hedge firm payment commitments assumed with suppliers and service providers from changes in the BRL vs USD exchange rate. For the commitments whose payment occurred in 2015, the hedge was set up, mainly, in Jan'15 and for the commitments whose payment occurs in 2016, the hedge was set up, mainly, in Dec'15. Therefore, the expenses related to those commitments recognized in 3Q15 were referenced on the exchange rate of Jan'15, while those commitments recognized in 3Q16 were referenced in the exchange rate of Dec'15 and were impacted by the depreciation of the BRL versus USD between Jan'15 and Dec'15. In the Financial Statements see note 4.d – Cash Flow Hedge.

<sup>6</sup> Includes expenses with legal publications, auditors, appraisers, and lawyers, among other professionals engaged as advisors for the transaction.

<sup>7</sup> Includes expenses with consulting services hired to help the integration planning of the proposed combination with Cetip which is subject to regulatory approvals.

<sup>8</sup> Reported in the financial statement, note 14, and in the Reference Form, item 4.3.II.2.1.

<sup>9</sup> Does not include the amount related to the shares of Bolsa Mexicana de Valores, Bolsa de Comercio de Santiago and Bolsa de Valores de Colombia owned by BM&FBOVESPA, which are treated as a financial investment and amounted to R\$203.1 million at the end of Sep'16.

<sup>10</sup> Total pretax proceeds from sales executed in Sep'15 (R\$1,201.3 million) and Apr'16 (R\$4,286.4 million).

hedged by swaps against changes in the Brazilian Real vs US Dollar exchange rate. Additionally, in Sep'16, the Company entered into NDFs (non-deliverable forwards) to hedge for FX certain future interest payments for the 2020 Notes.

**Financial Result:** reached R\$221.5 million in 3Q16, 157.5% above the previous year's third quarter:

**Financial income:** totaled R\$325.1 million, 83.9% higher in 3Q16, mainly explained by a higher average financial investments balance, which includes proceeds from the sale of CME Group shares, in Sep'15 and Apr'16.

**Financial expenses:** amounted to R\$103.6 million, 14.2% higher over 3Q15, mainly explained by: (i) R\$62.8 million regarding transactions with derivatives to hedge the 2020 Notes<sup>11</sup>; and (ii) maintenance of stand-by facilities, available but not drawn, in connection with the transaction with Cetip.

**Income tax and social contributions:** totaled R\$41.9 million in 3Q16. Current taxes and social contribution totaled R\$5.9 million and includes R\$2.5 million in taxes paid by the BM&FBOVESPA Bank, with cash impact. Deferred taxes reached R\$35.9 million, with no cash impact, composed of R\$135.3 million related to temporary differences from the amortization of goodwill for tax purposes in 3Q16 and by deferred taxes amounting to R\$99.3 million (positive), mainly explained by the creation of tax related to provision expenses.

**Net income (attributable to shareholders):** totaled R\$293.5 million in 3Q16, 85.4% lower over 3Q15. The comparison with the same period of the previous year is impacted by extraordinary items in both periods, in 3Q15, impacts related to the partial divestment in CME Group shares; and in 3Q16, extraordinary expenses related to provisions, as mentioned above.

Excluding extraordinary items that impacted the Company's results, the quarterly net income would have amounted to R\$453.2 million

#### 3Q16 extraordinary items (in R\$ millions)

	Income statement line impacted	Before Tax	After Tax
Provisions related to lawsuit	Expenses	183.9	121.4
Provisions related to success fees	Expenses	47.4	33.6
Transaction with Cetip	Expenses	7.2	4.7
<b>Total extraordinary items</b>		<b>238.5</b>	<b>159.7</b>

**CAPEX:** capital expenditures totaled R\$49.2 million in 3Q16, of which R\$43.3 million was invested in technology and infrastructure, particularly in the equities phase of the new integrated BM&FBOVESPA Clearinghouse. In the nine months of 2016, capital expenditures reached R\$157.2 million. The 2016 CAPEX budget ranges from R\$200 million to R\$230 million.

**Interest on Capital:** on November 11, 2016, the Company's Board of Directors approved the distribution of R\$146.7 million in interest on capital to be paid on December 2, 2016, based on the shareholders' position dated November 21, 2016, representing 50% of the IFRS net income in the quarter.

## PERFORMANCE BY SEGMENT

**BM&F segment:** ADV for the derivatives market reached 2.9 million contracts in 3Q16, a decrease of 11.7% in comparison with 3Q15. This performance is mainly explained by lower volumes in most groups of contracts, especially Interest rates in BRL contracts (-32.7%), which was partially offset by higher volumes of Mini contracts (+66.9%).

Average RPC reached R\$1.247, down 12.9% year-over-year. This reduction is explained by: (i) higher participation of Mini contracts in the overall ADV, given that these contracts have a significantly lower average RPC; (ii) the appreciation of 4.7% of the BRL against USD, negatively impacting the RPC of contracts priced in this foreign currency, mainly the FX rates (-6.0%) and Interest rates in USD (-16.7%) contracts.

**Bovespa segment:** ADTV for equities reached R\$6.9 billion in 3Q16, 5.9% higher compared with the same period of the previous year, reflecting a combination of a higher average market capitalization (+9.7%) with a lower turnover velocity, which reached 69.4% in 3Q16 versus 70.8% in 3Q15.

Trading and post-trading margins were close to flat, reaching 5.268 bps in 3Q16 versus 5.246 bps in 3Q15.

#### Other high growth products:

- ✓ **Tesouro Direto** maintained its growth trend, with average assets under custody growing 86.4% year-over-year, to R\$35.7 billion in 3Q16. The average number of investors reached 358.0 thousand in 3Q16, up 80.3% in the year-over-year comparison.

## UPDATE ON STRATEGIC INITIATIVES

**Merger between BM&FBOVESPA and Cetip:** the business combination between BM&FBOVESPA and Cetip, approved by both companies' shareholders on May 20, is still awaiting regulatory approval from CVM, BACEN and CADE. This transaction, which will combine the talents and strengths of both companies, will result in the creation of a world-class infrastructure, with major systemic importance, boosting the security, soundness and efficiency of the Brazilian market. The Company has dedicated efforts to plan the business combination, respecting the ground rules set by the antitrust authorities, setting up work teams to assure that the integration steps are done in a manner to maintain the operating and technological excellence in delivering services for the market and regulators, improve the services offered to clients, as well as, capture potential synergies.

<sup>11</sup> In Mar'16, the Company entered into swap transactions to hedge the 2020 Notes principal amount in foreign currency, switching the exchange variation risk to a short position in local interest rates. In Sep'16, the Company entered into NDFs (non-deliverable forwards) to hedge the 2020 Notes coupon from exchange variation. See Financial Statement Note 4.d - Fair value hedge and Cash flow hedge.

**BM&FBOVESPA Clearinghouse (post-trading integration):** in 3Q16 started the parallel production process of the second phase of the BM&FBOVESPA Clearinghouse, which will migrate the equity and corporate fixed income markets to a new infrastructure, integrating these markets with financial, commodities and OTC derivatives markets. The parallel production process replicates in the BM&FBOVESPA Clearinghouse's environment all the post-trading activities occurring in the production environment of each market. Since Jul'16, 10 parallel production cycles were conducted and BM&FBOVESPA expects that its systems and processes along with most of its market participants will reach the required readiness and stability by Dec'16. Therefore, BM&FBOVESPA choose to extend the projects schedule, including further parallel production cycles at the beginning of 2017, and migrating in the first quarter of 2017, during the Carnival public holiday.

**IPCA (Inflation) Spread Future contract:** with the increase in liquidity of the Inflation Spread Future contract, which has been traded with the participation of Market Makers since May'16, BM&FBOVESPA has worked in partnership with market participants to change the settlement price calculation methodology for this contract, with the aim of further increasing its liquidity, and since Aug'16 the contract has been traded with new trading hours and with the implementation of an electronic call. This contract reached a total of 100 thousand open interest contracts at the beginning of Aug'16, with an ADV of 2.1 thousand contracts in 3Q16 in 14 of 16 different maturities, traded by more than 40 counterparties.

**Exchange Traded Fund (ETF):** in Aug'16, a new fee policy was implemented for Market Makers, that exempts them from paying exchange fees and settlement fees on hedge transactions with equities that compose the theoretical portfolio of the index tracked by the respective ETF. Additionally, a new ETF referenced in the Bovespa index (BOVV11) was launched, expanding to 15 the number of ETFs available. The ADTV of this type of contract in 3Q16 reached R\$170.8 million, 20.1% higher than the same period of the previous year.

**Enhancements to the Special Listing Segments:** another important stage in the process of promoting enhancements to the Special Listing Segments was concluded in 3Q16. This process began in Mar'16 through a detailed analysis made by BM&FBOVESPA on corporate governance best practices adopted in more than 20 jurisdictions jointly with a public consultation that had broad engagement of investors, listed companies and market entities. After the consolidation of the results, BM&FBOVESPA proposed a series of changes to the rules of Novo Mercado and Level 2 and led a public hearing with all market participants, which was concluded in Sep'16. Based on the answers received in the public hearing, BM&FBOVESPA proposed a new version of Novo Mercado and Level 2 regulations and, in Nov'16, started another round of public hearing with all stakeholders to discuss it. When this phase is completed, the Company will organize a restricted hearing only with the companies listed in special segments to deliberate on the changes.

## RECONCILIATION OF ADJUSTED NET INCOME

	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)	9M16	9M15	9M16/9M15 (%)
<b>IRFS net income*</b>	<b>293.5</b>	<b>2,012.5</b>	<b>-85.4%</b>	<b>(114.4)</b>	<b>-356.5%</b>	<b>518.4</b>	<b>2,610.0</b>	<b>-80.1%</b>
Stock grant/option (recurring net of tax)	13.9	12.8	8.6%	27.2	-48.8%	57.9	37.6	53.9%
Deferred tax liabilities	135.3	137.5	-1.6%	135.3	-	405.9	412.6	-1.6%
Equity in Income of Investees (net of taxes)	-	(37.6)	-	-	-	(19.6)	(106.8)	-81.7%
Expenses related to Cetip's transaction (net of tax)	4.7	-	-	31.5	-85.0%	36.9	-	-
Divestment in CME Group shares (net of tax)	-	-	-	557.3	-	557.3	-	-
IOF on proceeds from CME Group shares sale (net of tax)	-	-	-	10.8	-	10.8	-	-
IoC Adjustments	-	(49.0)	-	-	-	-	(49.0)	-
Discontinuity of the equity method (net of taxes)	-	(1,145.0)	-	-	-	-	(1,145.0)	-
Results from the selling of the CME Group (net of taxes)	-	(474.2)	-	-	-	-	(474.2)	-
Non-recurring expenses with provisions (net of tax)	155.0	-	-	-	-	155.0	-	-
<b>Adjusted net income</b>	<b>602.4</b>	<b>457.0</b>	<b>31.8%</b>	<b>647.7</b>	<b>-7.0%</b>	<b>1,722.5</b>	<b>1,285.1</b>	<b>34.0%</b>

\*Attributable to BM&FBOVESPA shareholders.

## SUMMARY OF CONSOLIDATED BALANCE SHEET

ASSETS (In R\$ thousands)	Sep 30, 2016	Dec 31, 2015	LIABILITIES AND EQUITY (In R\$ thousands)	Sep 30, 2016	Dec 31, 2015
<b>Current assets</b>	<b>9,067,627</b>	<b>8,673,786</b>	<b>Current liabilities</b>	<b>3,497,508</b>	<b>2,096,785</b>
Cash and cash equivalents	546,764	440,845	Collateral for transactions	1,605,634	1,338,010
Financial investments	8,210,900	7,798,529	Others	1,891,874	758,775
Others	309,963	434,412	<b>Noncurrent liabilities</b>	<b>5,038,325</b>	<b>5,859,897</b>
<b>Noncurrent assets</b>	<b>18,084,970</b>	<b>17,635,109</b>	Debt issued abroad	1,993,660	2,384,084
<b>Long-term receivables</b>	<b>2,335,925</b>	<b>1,961,426</b>	Deferred inc. tax and social contrib.	2,617,140	3,272,276
Financial investments	2,162,759	1,815,620	Others	427,525	203,537
Others	173,166	145,806	<b>Equity</b>	<b>18,616,764</b>	<b>18,352,213</b>
<b>Investments</b>	<b>29,496</b>	<b>30,635</b>	Capital	2,540,239	2,540,239
<b>Property and equipment, net</b>	<b>455,211</b>	<b>453,094</b>	Capital reserve	14,284,660	14,300,310
<b>Intangible assets</b>	<b>15,264,338</b>	<b>15,189,954</b>	Others	1,782,148	1,501,550
Goodwill	14,401,628	14,401,628	<b>Non-controlling interests</b>	<b>9,717</b>	<b>10,114</b>
<b>Total Assets</b>	<b>27,152,597</b>	<b>26,308,895</b>	<b>Total liabilities and equity</b>	<b>27,152,597</b>	<b>26,308,895</b>



## CONSOLIDATED INCOME STATEMENT

<i>(In thousand of Brazilian Reals, unless otherwise indicated)</i>	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)	9M16	9M15	9M16/9M15 (%)
<b>Total revenues</b>	<b>621,281</b>	<b>662,901</b>	<b>-6.3%</b>	<b>637,851</b>	<b>-2.6%</b>	<b>1,884,519</b>	<b>1,855,557</b>	<b>1.6%</b>
<b>Trading/settlement - BM&amp;F</b>	<b>240,550</b>	<b>306,759</b>	<b>-21.6%</b>	<b>272,258</b>	<b>-11.6%</b>	<b>790,544</b>	<b>815,709</b>	<b>-3.1%</b>
Derivatives	235,975	300,921	-21.6%	266,805	-11.6%	775,088	800,345	-3.2%
Foreign exchange	4,575	5,838	-21.6%	5,453	-16.1%	15,456	15,240	1.4%
Securities	-	-	-	-	-	-	124	-
<b>Trading/settlement - Bovespa</b>	<b>241,795</b>	<b>221,858</b>	<b>9.0%</b>	<b>238,998</b>	<b>1.2%</b>	<b>704,925</b>	<b>680,209</b>	<b>3.6%</b>
Trading fees	38,745	35,438	9.3%	38,312	1.1%	113,076	108,054	4.6%
Clearing fees	198,567	184,289	7.7%	196,078	1.3%	578,349	557,060	3.8%
Others	4,483	2,131	110.4%	4,608	-2.7%	13,500	15,095	-10.6%
<b>Other revenues</b>	<b>138,936</b>	<b>134,284</b>	<b>3.5%</b>	<b>126,595</b>	<b>9.7%</b>	<b>389,050</b>	<b>359,639</b>	<b>8.2%</b>
Securities lending	30,179	28,246	6.8%	24,329	24.0%	77,664	77,740	-0.1%
Listing	13,129	13,226	-0.7%	12,915	1.7%	39,599	37,825	4.7%
Depository, custody and back-office	47,409	36,159	31.1%	42,592	11.3%	126,466	103,105	22.7%
Trading access (Brokers)	8,654	9,941	-12.9%	9,338	-7.3%	27,771	29,660	-6.4%
<i>Vendors</i>	24,624	30,459	-19.2%	24,197	1.8%	76,119	68,200	11.6%
BM&FBOVESPA bank	9,880	10,010	-1.3%	9,574	3.2%	28,780	25,170	14.3%
Others	5,061	6,243	-18.9%	3,650	38.7%	12,651	17,939	-29.5%
<b>Revenue deductions</b>	<b>(62,135)</b>	<b>(64,574)</b>	<b>-3.8%</b>	<b>(63,377)</b>	<b>-2.0%</b>	<b>(187,391)</b>	<b>(182,153)</b>	<b>2.9%</b>
PIS and Cofins	(53,456)	(56,247)	-5.0%	(54,967)	-2.7%	(162,056)	(158,611)	2.2%
Service tax	(8,679)	(8,327)	4.2%	(8,410)	3.2%	(25,335)	(23,542)	7.6%
<b>Net revenues</b>	<b>559,146</b>	<b>598,327</b>	<b>-6.5%</b>	<b>574,474</b>	<b>-2.7%</b>	<b>1,697,128</b>	<b>1,673,404</b>	<b>1.4%</b>
<b>Expenses</b>	<b>(446,143)</b>	<b>(217,824)</b>	<b>104.8%</b>	<b>(268,786)</b>	<b>66.0%</b>	<b>(916,966)</b>	<b>(637,262)</b>	<b>43.9%</b>
Personnel	(105,206)	(106,425)	-1.1%	(125,953)	-16.5%	(337,434)	(336,467)	0.3%
Data processing	(36,882)	(30,400)	21.3%	(34,329)	7.4%	(107,067)	(90,027)	18.9%
Deprec. and amortization	(25,136)	(26,125)	-3.8%	(23,766)	5.8%	(72,716)	(84,822)	-14.3%
Third-party services	(14,396)	(12,601)	14.2%	(8,580)	67.8%	(30,595)	(29,636)	3.2%
Maintenance	(3,927)	(3,529)	11.3%	(3,801)	3.3%	(11,468)	(9,878)	16.1%
Communication	(1,376)	(1,030)	33.6%	(1,125)	22.3%	(4,105)	(4,408)	-6.9%
Marketing	(1,683)	(4,689)	-64.1%	(1,624)	3.6%	(4,888)	(8,034)	-39.2%
Taxes	(1,706)	(1,914)	-10.9%	(1,826)	-6.6%	(5,353)	(5,472)	-2.2%
Board/committees compensation	(2,467)	(2,387)	3.4%	(2,516)	-1.9%	(7,290)	(6,794)	7.3%
Transaction with Cetip	(7,163)	-	-	(47,785)	-85.0%	(55,955)	-	-
Others	(246,201)	(28,724)	757.1%	(17,481)	1308.4%	(280,095)	(61,724)	353.8%
<b>Operating income</b>	<b>113,003</b>	<b>380,503</b>	<b>-70.3%</b>	<b>305,688</b>	<b>-63.0%</b>	<b>780,162</b>	<b>1,036,142</b>	<b>-24.7%</b>
<i>Operating margin</i>	<i>20.2%</i>	<i>63.6%</i>	<i>-4,338 bps</i>	<i>53.2%</i>	<i>-3,300 bps</i>	<i>46.0%</i>	<i>61.9%</i>	<i>-1,595 bps</i>
<b>Equity in income of investees</b>	<b>-</b>	<b>49,013</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>136,245</b>	<b>-</b>
<b>Discontinuity of the Equity method</b>	<b>-</b>	<b>1,734,889</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,734,889</b>	<b>-</b>
<b>Gain on disposal of investment in associate</b>	<b>-</b>	<b>723,995</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>723,995</b>	<b>-</b>
<b>Financial result</b>	<b>221,525</b>	<b>86,030</b>	<b>157.5%</b>	<b>(418,290)</b>	<b>-153.0%</b>	<b>(36,222)</b>	<b>218,974</b>	<b>-116.5%</b>
Financial income	325,116	176,772	83.9%	284,244	14.4%	838,867	409,380	104.9%
Financial expenses	(103,591)	(90,742)	14.2%	(129,734)	-20.2%	(302,289)	(190,406)	58.8%
Divestment from CME Group shares	-	-	-	(572,800)	-	(572,800)	-	-
<b>Income before taxes</b>	<b>334,528</b>	<b>2,974,430</b>	<b>-88.8%</b>	<b>(112,602)</b>	<b>-397.1%</b>	<b>743,940</b>	<b>3,850,245</b>	<b>-80.7%</b>
<b>Income tax and social contribution</b>	<b>(41,870)</b>	<b>(961,502)</b>	<b>-95.6%</b>	<b>(1,541)</b>	<b>2617.1%</b>	<b>(225,945)</b>	<b>(1,239,301)</b>	<b>-81.8%</b>
Current	(5,922)	(195,877)	-97.0%	(907,790)	-99.3%	(927,009)	(215,714)	329.7%
Deferred	(35,948)	(765,625)	-95.3%	906,249	-104.0%	701,064	(1,023,587)	-168.5%
<b>Net income (loss)</b>	<b>292,658</b>	<b>2,012,928</b>	<b>-85.5%</b>	<b>(114,143)</b>	<b>-356.4%</b>	<b>517,995</b>	<b>2,610,944</b>	<b>-80.2%</b>
<i>Net margin</i>	<i>52.3%</i>	<i>336.4%</i>	<i>-28,409 bps</i>	<i>-19.9%</i>	<i>7,221 bps</i>	<i>30.5%</i>	<i>156.0%</i>	<i>-12,550 bps</i>
<b>Attributable to:</b>								
BM&FBOVESPA's shareholders	293,466	2,012,519	-85.4%	(114,401)	-356.5%	518,392	2,609,985	-80.1%
<i>Net margin</i>	<i>52.5%</i>	<i>336.4%</i>	<i>-28,387 bps</i>	<i>-19.9%</i>	<i>7,240 bps</i>	<i>30.5%</i>	<i>156.0%</i>	<i>-12,542 bps</i>
Minority interest	(808)	409	-297.6%	258	-413.2%	(397)	959	-141.4%
Sharecount	1,787,403,276	1,787,049,094	0.0%	1,786,959,763	0.0%	1,786,929,084	1,791,892,507	-0.3%
<b>EPS attrib. to BM&amp;FBOVESPA's shareholders</b>	<b>0.164186</b>	<b>1.126169</b>	<b>-85.4%</b>	<b>(0.064020)</b>	<b>-356.5%</b>	<b>0.290102</b>	<b>1.456552</b>	<b>-80.1%</b>
<b>Adjusted expenses</b>	<b>(155,470)</b>	<b>(163,601)</b>	<b>-5.0%</b>	<b>(146,671)</b>	<b>6.0%</b>	<b>(446,482)</b>	<b>(443,915)</b>	<b>0.6%</b>

## STATISTICAL OPERATING DATA FOR BM&F SEGMENT

### AVERAGE DAILY VOLUME – ADV (thousand contracts)

Contracts	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
Interest rates in BRL	1,206.0	1,790.9	-32.7%	1,397.0	-13.7%
FX rates	386.4	473.2	-18.3%	411.3	-6.1%
Stock indices	78.7	101.1	-22.2%	97.6	-19.3%
Interest rates in USD	229.3	321.5	-28.7%	264.5	-13.3%
Commodities	8.8	9.0	-2.2%	7.6	17.0%
Mini contracts	996.9	597.3	66.9%	829.3	20.2%
<b>TOTAL</b>	<b>2,906.2</b>	<b>3,293.0</b>	<b>-11.7%</b>	<b>3,007.2</b>	<b>-3.4%</b>

### REVENUE PER CONTRACT - RPC (In R\$)

Contracts	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
Interest rates in BRL	1.261	1.108	13.8%	1.224	3.0%
FX rates	3.500	3.725	-6.0%	3.967	-11.8%
Stock indices	1.662	2.005	-17.1%	1.937	-14.2%
Interest rates in USD	1.562	1.874	-16.7%	1.897	-17.7%
Commodities	2.295	2.431	-5.6%	2.075	10.6%
Mini contracts	0.241	0.232	4.0%	0.269	-10.4%
<b>TOTAL</b>	<b>1.247</b>	<b>1.431</b>	<b>-12.9%</b>	<b>1.420</b>	<b>-12.2%</b>



## STATISTICAL OPERATING DATA FOR BOVESPA SEGMENT

### AVERAGE DAILY TRADED VALUE - ADTV (In R\$ millions)

Market	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
<b>Stocks and equity deriv.</b>	6,928.0	6,539.6	5.9%	7,141.9	-3.0%
Cash market	6,683.1	6,293.4	6.2%	6,872.4	-2.8%
Derivatives	244.9	246.2	-0.5%	269.5	-9.1%
Options market (stocks / indices)	179.6	173.3	3.6%	209.2	-14.1%
Forward market	65.3	72.8	-10.3%	60.3	8.3%
<b>Fixed income and other cash-market securities</b>	2.9	5.5	-46.9%	1.7	73.3%
<b>TOTAL</b>	<b>6,930.9</b>	<b>6,545.1</b>	<b>5.9%</b>	<b>7,143.6</b>	<b>-3.0%</b>

### AVERAGE DAILY NUMBER OF TRADES (in thousands)

Market	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
<b>Stocks and equity deriv.</b>	890.0	953.4	-6.7%	950.7	-6.4%
Cash market	836.1	896.0	-6.7%	892.5	-6.3%
Derivatives	53.9	57.4	-6.0%	58.2	-7.3%
Options market (stocks / indices)	53.4	56.9	-6.2%	57.7	-7.4%
Forward market	0.5	0.5	16.3%	0.5	10.5%
<b>Fixed income and other cash-market securities</b>	0.013	0.009	44.4%	0.012	7.2%
<b>TOTAL</b>	<b>890.0</b>	<b>953.4</b>	<b>-6.7%</b>	<b>950.7</b>	<b>-6.4%</b>

### OTHER OPERATIONAL STATISTICS

	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
Average market cap. (in R\$ billions)	2,398.5	2,186.4	9.7%	2,155.6	11.3%
Average Ibovespa (closing price)	57,171	48,568	17.7%	50,983	12.1%
Average value under custody (in R\$ billions)	1,233.7	1,046.9	17.8%	1,076.5	14.6%
Average value under custody - ex ADRs and Forgn. Inv. (in R\$ billions)	444.3	388.3	14.4%	381.3	16.5%
Number of custody accounts - average	578,295	581,167	-0.5%	582,706	-0.8%
Treasury Direct platform (average assets under custody - R\$ billions)	35.7	19.2	86.4%	31.6	13.1%
ETFs ADTV (in R\$ millions)	170.8	142.2	20.1%	187.5	-8.9%
# Listed companies to trade stocks	435	453	-4.0%	440	-1.1%
Turnover velocity (annualized)	69.4%	70.8%	-141 bps	79.4%	-1,000 bps

### TRADING MARGINS (basis points)

Market	3Q16	3Q15	3Q16/3Q15 (%)	2Q16	3Q16/2Q16 (%)
<b>Stocks and equity derivatives</b>	5.267	5.247	0.02 bps	5.206	0.06 bps
Cash market	4.922	4.939	-0.02 bps	4.850	0.07 bps
Derivatives	14.679	13.110	1.57 bps	14.298	0.38 bps
Options market	15.290	13.157	2.13 bps	14.672	0.62 bps
Forward market	12.999	12.999	0.00 bps	12.999	0.00 bps
<b>TOTAL</b>	<b>5.268</b>	<b>5.246</b>	<b>0.02 bps</b>	<b>5.208</b>	<b>0.06 bps</b>